Daniel Alkon Net Worth

Daniel Alkon biography

Dr. Daniel Alkon, M.D., serves as President, Chief Scientific Officer of the Company. Dr. Alkon has been the founding Scientific Director of BRNI since 1999. He received his undergraduate degree in chemistry in 1965 at the University of Pennsylvania. After earning his M.D. at Cornell University and finishing an internship in medicine at the Mount Sinai Hospital in New York, he joined the staff of the National Institutes of Health where during his 30 year career he became a Medical Director in the U.S. Public Health Service at the National Institute of Neurological Disorders and Strokes and Chief of the Laboratory of Adaptive Systems. Dr. Alkon occupied the Toyota Chair in Neurodegenerative diseases at BRNI from June 2006 until September 23, 2016. In this position, he and his team conducted multidisciplinary research on the molecular and biophysical mechanisms of memory and memory dysfunction in psychiatric and neurological disorders, particularly Alzheimer’s disease. From October 2000 until September 23, 2016, he was also a Professor at BRNI and a Professor of Neurology at West Virginia University.

How old is Daniel Alkon?

Daniel Alkon is 73, he's been the President and Chief Scientific Officer of NextTrip since 2016. There are 1 older and 3 younger executives at NextTrip. The oldest executive at NextTrip Inc. is William Singer, 74, who is the Vice Chairman of the Board.

What's Daniel Alkon's mailing address?

Daniel's mailing address filed with the SEC is C/O NEUROTROPE, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036.

Insiders trading at NextTrip

Over the last 10 years, insiders at NextTrip have traded over $2,644 worth of NextTrip stock and bought 245,000 units worth $210,900 . The most active insiders traders include Bruce Bernstein, Ivan P. Gergel, and Andrew D Perlman. On average, NextTrip executives and independent directors trade stock every 180 days with the average trade being worth of $69,913. The most recent stock trade was executed by Jonathan Schechter on 30 October 2020, trading 25,000 units of NTRP stock currently worth $24,500.

What does NextTrip do?

sigma labs, inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3d printing, and other advanced manufacturing technologies. sigma labs is pioneering the commercialization of in-process metallurgical and geometric quality assurance monitoring technology. printrite3d® with its software modules inspect™, contour™ and analytics™ is the industry's first, commercially available, platform independent, third party in-process quality monitoring system for metal additive manufacturing. it is available as a fully embedded oem installation or a stand-alone connection to your existing machines. additionally, sigma labs conducts contract metal 3d printing in materials inconnel718, 316 stainless, titanium, aluminum and ms1 tool steel. for more information please visit www.sigmalabsinc.com. for inquiries contact: sales@sigmalabsinc.com follow sigma labs on twi

NextTrip executives and stock owners

NextTrip executives and other stock owners filed with the SEC include:

• Robert Weinstein,
  Chief Financial Officer, Executive Vice President
• Jonathan Schechter,
  Director
• Kenneth Gorelick,
  Director
• Ivan Gergel,
  Director
• Bruce Bernstein,
  Director
• Paula Trzepacz,
  Executive Vice President and Chief Medical Officer
• William Singer,
  Vice Chairman of the Board
• Charles Ryan,
  Chief Executive Officer, Director
• Daniel Alkon,
  President, Chief Scientific Officer
• Joshua Silverman,
  Chairman of the Board
• Shana Phares,
  Director
• George Perry,
  Director
• Michael Ciraolo,
  COO and General Counsel
• Susanne Wilke,
  Director
• James Gottlieb,
  Director
• Andrew D Perlman,
  Director
• Warren W Wasiewski,
  
• Paul E. Freiman,
  See Remarks
• Charles S Ramat,
  President and CEO
• Larry Douglas Altstiel,
  Director
• Jay M Haft,
  Director
• John H Abeles,
  10% owner
• David Crockford,